“Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion”
April 16, 2024
“Vertex Pharmaceuticals VRTX -0.02%decrease; red down pointing triangle has agreed to acquire Alpine Immune Sciences ALPN -0.01%decrease; red down pointing triangle for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.
The companies said Wednesday that Vertex would pay $65 a share for Alpine. Net of expected cash to be acquired the deal is valued at roughly $4.6 billion. The acquisition is the largest in Vertex’s history, a spokeswoman for Vertex said…”